Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ACAD

ACADIA Pharmaceuticals Inc.

Healthcare | Biotechnology

No licensed closing price on file for ACAD. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$2.23

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:31 UTC.

What ACADIA Pharmaceuticals Inc. does

Ultragenyx Pharmaceutical is a biopharmaceutical company developing treatments for neurological and rare diseases. The company's two main commercial products are NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, which together generated net product sales of $1,071.5 million in 2025, up from $957.8 million in 2024.

Summarized from ACADIA Pharmaceuticals Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$2.23
Return on equity31.86%

Revenue, margins & earnings

FY2021: net loss $168M on revenue $484M$484MFY2021FY2022: net loss $216M on revenue $517M$517MFY2022FY2023: net loss $61M on revenue $726M$726MFY2023FY2024 Net income: $226MFY2024 Operating costs: $727M$958MFY2024FY2025 Revenue: $1.07B — margin split not shown (non-operating gains)$1.07BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-07
  • 2026-08-07EVP, CHIEF FINANCIAL OFFICERSale-5,849$169.6K
  • 2026-08-07EVP, CHIEF FINANCIAL OFFICEROption exercise14,292$255.0K
  • 2026-08-07EVP, CHIEF FINANCIAL OFFICERSale-9,292$272.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does ACADIA Pharmaceuticals Inc. do?

Ultragenyx Pharmaceutical is a biopharmaceutical company developing treatments for neurological and rare diseases.

When did ACAD last file with the SEC?

ACADIA Pharmaceuticals Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:31 UTC. This page is also available as JSON at /api/data?ticker=ACAD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACAD and 5,000+ tickers.

Create a free account — keep ACAD
For your agent
GET /api/data?ticker=ACAD

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt